A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Prior treatment

• Prior therapy with antibody or drug specifically targeting T-cell costimulation or checkpoint pathway; prior treatment with bevacizumab or its biosimilars
• Prior history of \>= Grade 2 hepatic encephalopathy
• Prior allogeneic stem cell transplantation or organ transplantation
• Administered a live vaccine \<=28 days before randomization
  • NOTE: Other protocol Inclusion/Exclusion criteria may apply

Other illness

• Leptomeningeal disease or uncontrolled, untreated brain metastasis
• Active autoimmune diseases or history of autoimmune diseases that may relapse
• History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases
• Infection (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days of randomization
• Untreated or incompletely treated esophageal or gastric varices with bleeding or high risk of bleeding
• History of severe hypersensitivity reactions to other monoclonal antibodies

Other

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology
• Significant cardiovascular risk factors

• Histologically confirmed HCC
• Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease that was not amenable to or had progressed after loco-regional therapy, and was not amenable to a curative treatment approach
• Tumor tissue required for an evaluable programmed cell death protein-ligand 1 (PD-L1) expression result
• No prior systemic therapy for HCC
• At least 1 measurable lesion as defined per RECIST v1.1
• Adequate organ function during screening and before randomization

Criteria the registry did not label

• Criteria: